Century Therapeutics/IPSC

$3.09

3.86%
-
1D1W1MYTD1YMAX

About Century Therapeutics

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.

Ticker

IPSC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brent Pfeiffenberger

Employees

152

Headquarters

Philadelphia, United States

IPSC Metrics

BasicAdvanced
$229.16M
Market cap
-
P/E ratio
-$2.30
EPS
-
Beta
-
Dividend rate
$229.16M
$5.51
$1.28
216.75K
9.918
-32.26%
-56.07%
-34.19%
102.533
0.927
1.24
-57.01%
-1.49%

What the Analysts think about IPSC

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
379.94% upside
High $24.00
Low $9.00
$3.09
Current price
$14.83
Average price target

IPSC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-19,650% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$200K
100%
Net income
$-39.3M
20.18%
Profit margin
-19,650%
-39.91%

IPSC Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 17.27%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.53
-$0.56
-$0.55
-$0.65
-
Expected
-$0.52
-$0.54
-$0.51
-$0.55
-$0.50
Surprise
1.25%
2.89%
7.3%
17.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Century Therapeutics stock?

Century Therapeutics (IPSC) has a market cap of $240.06M as of April 20, 2024.

What is the P/E ratio for Century Therapeutics stock?

The price to earnings (P/E) ratio for Century Therapeutics (IPSC) stock is 0 as of April 20, 2024.

Does Century Therapeutics stock pay dividends?

No, Century Therapeutics (IPSC) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Century Therapeutics dividend payment date?

Century Therapeutics (IPSC) stock does not pay dividends to its shareholders.

What is the beta indicator for Century Therapeutics?

Century Therapeutics (IPSC) does not currently have a Beta indicator.

What is the Century Therapeutics stock price target?

The target price for Century Therapeutics (IPSC) stock is $14.83, which is 379.94% above the current price of $3.09. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Century Therapeutics stock

Buy or sell Century Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing